Table 3. Pharmacokinetic parameters of paroxetine and pravastatin after oral administration in diabetic rats on d 1 and 28 of treatment. Data represent the mean±SEM of 5–6 rats. bP<0.05, cP<0.01 vs DM-PA or DM-PR on d 1. fP<0.01 vs DM-PA or DM-PR on d 28.
| t1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC0–t (h·ng/mL) | AUC0–∞ (h·ng/mL) | Cl/F (L·h−1·kg−1) | MRT (h) | ||
|---|---|---|---|---|---|---|---|---|
| Paroxetine | ||||||||
| d 1 | DM-PA | 3.21±0.34 | 2.70±0.54 | 63.56±7.28 | 529.78±55.28 | 535.35±56.44 | 19.98±3.08 | 6.49±0.21 |
| DM-CO | 3.48±0.33 | 2.40±0.40 | 129.16±18.55b | 717.50±37.18b | 729.33±39.40b | 14.58±0.97 | 5.63±0.42 | |
| d 28 | DM-PA | 3.94±0.25 | 1.83±0.11 | 73.95±10.02 | 490.71±24.62 | 514.75±33.47 | 21.68±1.55 | 6.64±0.26 |
| DM-CO | 3.52±0.31 | 2.00±0.00 | 252.20±33.77f | 1134.77±115.49f | 1143.13±115.74f | 9.47±1.45f | 4.55±0.29f | |
| Pravastatin | ||||||||
| d 1 | DM-PR | 1.50±0.09 | 0.25±0.00 | 31.85±4.64 | 26.94±1.31 | 31.75±1.25 | 317.02±13.13 | 1.16±0.05 |
| DM-CO | 0.93±0.19b | 0.55±0.05c | 89.56±5.00c | 121.46±11.43c | 128.83±10.28c | 79.54±6.02c | 1.23±0.04 | |
| d 28 | DM-PR | 1.95±0.24 | 0.25±0.00 | 8.38±1.68 | 14.68±2.88 | 18.96±3.01 | 585.52±93.86 | 1.50±0.05 |
| DM-CO | 1.23±0.23 | 0.55±0.05f | 29.12±2.76f | 43.05±6.65f | 47.68±6.00f | 222.56±25.55f | 1.30±0.06 | |
AUC0–t of paroxetine was AUC0–24 and AUC0–t of pravastatin was AUC0–4.